Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)716.00
  • Today's Change-8.00 / -1.10%
  • Shares traded58.55k
  • 1 Year change+26.95%
  • Beta0.1796
Data delayed at least 20 minutes, as of Nov 13 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on £1000

1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)+33.51%
NAVInternational Biotechnology Trust (Ordinary Share)+34.90%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Key statistics

International Biotechnology Trust (IBT:LSE) set a new 52-week high during Tuesday's trading session when it reached 734.00. Over this period, the share price is up 24.31%.
52-week range
Today
555.00Nov 13 2023734.00Nov 12 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding36.40m
Market cap263.09m GBP
Total assets326.90m GBP
Total expense ratio1.16%
High724.00
Low716.00
Previous close724.00
Average volume178.48k
YTD Change+11.53%
Beta0.1796
Diluted NAV (est)820.11
Diluted NAV (last pub)824.06
Premium/Discount-11.60%
Net Gearing+10.05%
Annual div (ADY)28.40
GBX
Annual div yield (ADY)3.92%
Div ex-dateJul 25 2024
Div pay-dateAug 23 2024
Data delayed at least 20 minutes, as of Nov 13 2024 16:26 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.